Frequency of Acute Kidney Injury After the Initiation of Vitamin D Receptor Activators: A Multicenter Retrospective Observational Study

被引：0

作者：

Nakanishi, Masanori ^{[1
]}

Mizuno, Tomohiro ^{[1
]}

Sakai, Shinya ^{[2
]}

Hira, Daiki ^{[2
]}

Koseki, Takenao ^{[1
]}

Matsubara, Takeshi ^{[3
]}

Yokoi, Hideki ^{[3
]}

Yanagita, Motoko ^{[3
]}

Terada, Tomohiro ^{[2
]}

Yamada, Shigeki ^{[1
]}

Tsuboi, Naotake ^{[4
]}

机构：

[1] Fujita Hlth Univ, Dept Pharmacotherapeut & Informat, Sch Med, Kutsukakecho Dengakugakubo 1-98, Toyoake, Aichi 4701101, Japan

[2] Kyoto Univ Hosp, Dept Clin Pharmacol & Therapeut, 54 Shogoin Kawahara Cho,Sakyo Ku, Kyoto, Japan

[3] Kyoto Univ, Grad Sch Med, Dept Nephrol, Kyoto, Japan

[4] Fujita Hlth Univ, Dept Nephrol, Sch Med, Toyoake, Aichi, Japan

来源：

CLINICAL DRUG INVESTIGATION | 2025年

关键词：

DISEASE; ELDECALCITOL; OSTEOPOROSIS; PARICALCITOL;

D O I：

10.1007/s40261-025-01429-8

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background and Objectives: Vitamin D receptor activators (VDRAs) are widely used in patients with osteoporosis; however, the frequency of acute kidney injury (AKI) due to VDRAs is unclear. This study aimed to investigate whether the incidence of AKI after VDRA initiation differed among patients with different renal functions. Methods: The medical records of Japanese patients who were newly prescribed with VDRAs for osteoporosis at the Fujita Health University Hospital or Kyoto University Hospital between April 2012 and March 2022 were retrospectively reviewed in this study. The RIFLE (Risk, Injury, Failure, Loss of function, End-stage kidney disease) criteria were used to assess the incidence of AKI within 7 days after initiation of VDRA therapy. Additionally, the AKI algorithm was used to assess the incidence of AKI from 8 to 365 days after initiation of VDRA therapy. Results: The incidence of AKI, as defined by the RIFLE criteria, was significantly higher in patients with normal renal function or end-stage renal failure than in those with mild renal decline (p < 0.05); the incidence of AKI, defined using the AKI algorithm, showed a similar trend. We found that the lack of serum calcium level monitoring before the initiation of VDRAs might be a risk factor for AKI defined by the RIFLE criteria (odds ratio = 2.004, p = 0.096). Conclusions: The incidence of AKI after the initiation of VDRA therapy was high, even if renal function was normal. Thus, our results suggest that monitoring serum calcium levels before the initiation of VDRA therapy is necessary, regardless of renal function.

引用

页码：191 / 199

页数：9

共 20 条

[1] Isakova T., Nickolas T.L., Denburg M., Yarlagadda S., Weiner D.E., Gutierrez O.M., Et al., KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD), Am J Kidney Dis, 70, 6, pp. 737-751, (2017)
[2] Habas E., Eledrisi M., Khan F., Elzouki A.Y., Secondary hyperparathyroidism in chronic kidney disease: pathophysiology and management, Cureus, 13, 7, (2021)
[3] Hamdy N.A., Kanis J.A., Beneton M.N., Brown C.B., Juttmann J.R., Jordans J.G., Et al., Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure, BMJ, 310, 6976, pp. 358-363, (1995)
[4] Coburn J.W., Maung H.M., Elangovan L., Germain M.J., Lindberg J.S., Sprague S.M., Et al., Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4, Am J Kidney Dis, 43, 5, pp. 877-890, (2004)
[5] Wang A.Y., Fang F., Chan J., Wen Y.Y., Qing S., Chan I.H., Et al., Effect of paricalcitol on left ventricular mass and function in CKD: the OPERA trial, J Am Soc Nephrol, 25, 1, pp. 175-186, (2014)
[6] Rosen S., Greenfeld Z., Bernheim J., Rathaus M., Podjarny E., Brezis M., Hypercalcemic nephropathy: chronic disease with predominant medullary inner stripe injury, Kidney Int, 37, 4, pp. 1067-1075, (1990)
[7] Aihara S., Yamada S., Oka H., Kamimura T., Nakano T., Tsuruya K., Et al., Hypercalcemia and acute kidney injury induced by eldecalcitol in patients with osteoporosis: a case series of 32 patients at a single facility, Ren Fail, 41, 1, pp. 88-97, (2019)
[8] Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., Et al., Revised equations for estimated GFR from serum creatinine in Japan, Am J Kidney Dis, 53, 6, pp. 982-992, (2009)
[9] Bellomo R., Ronco C., Kellum J.A., Mehta R.L., Palevsky P., Acute renal failure: definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group, Crit Care, 8, 4, pp. R204-R212, (2004)
[10] Selby N.M., Hill R., Fluck R.J., Standardizing the early identification of acute kidney injury: the NHS England national patient safety alert, Nephron, 131, 2, pp. 113-117, (2015)

← 1 2 →